Movano (MOVE) 10-K 30 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 29, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	MOVANO INC.
Trading Symbol	MOVE
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		32,772,060
Entity Public Float			$ 122,155,856
Amendment Flag	false
Entity Central Index Key	0001734750
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-40254
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-0579295
Entity Address, Address Line One	6800 Koll Center Parkway
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94566
City Area Code	(415)
Local Phone Number	651-3172
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	Moss Adams LLP
Auditor Location	San Francisco
Auditor Firm ID	659

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,675	$ 5,710
Short-term investments	15,921
Payroll tax credit, current portion	166	500
Prepaid expenses and other current assets	1,296	691
Total current assets	35,058	6,901
Property and equipment, net	529	38
Payroll tax credit, noncurrent portion	630	134
Other assets	48	10
Total assets	36,265	7,083
Current liabilities:
Accounts payable	311	246
Paycheck Protection Program loan, current portion		248
Other current liabilities	2,907	666
Total current liabilities	3,218	1,160
Noncurrent liabilities:
Convertible promissory notes, net		11,342
Accrued interest		292
Paycheck Protection Program loan, noncurrent portion		103
Warrant liability		1,549
Derivative liability		121
Early exercised stock option liability	281	417
Other noncurrent liabilities	36	161
Total noncurrent liabilities	317	13,985
Total liabilities	3,535	15,145
Commitments and contingencies (Note 13)
Series A redeemable convertible preferred stock, $0.0001 par value, no and 2,692,253 shares authorized at December 31, 2021 and 2020; no and 2,692,253 shares issued and outstanding at December 31, 2021 and 2020; liquidation preference of $0 and $15,170 at December 31, 2021 and 2020		13,856
Series B redeemable convertible preferred stock, $0.0001 par value, no and 5,238,095 shares authorized at December 31, 2021 and 2020; no and 4,942,319 shares issued and outstanding at December 31, 2021 and 2020; liquidation preference of $0 and $21,858 at December 31, 2021 and 2020		18,962
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value, 5,000,000 and no shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020
Common stock, $0.0001 par value, 75,000,000 and 22,069,652 shares authorized at December 31, 2021 and 2020; 32,772,060 and 6,393,069 shares issued and outstanding at December 31, 2021 and 2020	3	1
Additional paid-in capital	97,506
Accumulated other comprehensive loss	(11)
Accumulated deficit	(64,768)	(40,881)
Total stockholders’ equity (deficit)	32,730	(40,880)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)	$ 36,265	$ 7,083

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	22,069,652
Common stock, shares issued	32,772,060	6,393,069
Common stock, shares outstanding	32,772,060	6,393,069
Series A Redeemable Convertible Preferred Stock
Preferred stock, shares par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized		2,692,253
Preferred stock, shares issued		2,692,253
Preferred stock, shares outstanding		2,692,253
Preferred stock, shares ,liquidation preference (in Dollars per share)	$ 0	$ 15,170
Series B Redeemable Convertible Preferred Stock
Preferred stock, shares par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized		5,238,095
Preferred stock, shares issued		4,942,319
Preferred stock, shares outstanding		4,942,319
Preferred stock, shares ,liquidation preference (in Dollars per share)	$ 0	$ 21,858

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
OPERATING EXPENSES:
Research and development	$ 13,427	$ 8,373
General and administrative	6,376	2,734
Total operating expenses	19,803	11,107
Loss from operations	(19,803)	(11,107)
Other income (expense), net:
Interest expense	(883)	(1,004)
Change in fair value of warrant liability	(1,581)	(1,511)
Change in fair value of derivative liability	121	564
Forgiveness of Paycheck Protection Program Loan	351
Interest and other income, net	22	27
Other income (expense), net	(1,970)	(1,924)
Net loss	(21,773)	(13,031)
Accretion and dividends on redeemable convertible preferred stock	(2,489)	(8,914)
Net loss attributable to common stockholders	(24,262)	(21,945)
Net loss	(21,773)	(13,031)
Other comprehensive loss:
Change in unrealized loss on available-for-sale securities	(11)
Total comprehensive loss	$ (21,784)	$ (13,031)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.92)	$ (6.85)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)	26,298,032	3,201,430

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series ARedeemable Convertible Preferred Stock	Series BRedeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 11,212	$ 12,692				$ (19,907)	$ (19,907)
Balance (in Shares) at Dec. 31, 2019	2,692,253	4,942,319	4,539,584
Stock-based compensation for stock grant				267			267
Stock-based compensation for stock grant (in Shares)			140,000
Stock-based compensation				446			446
Accretion of Series A and Series B redeemable convertible preferred stock	2,644	6,270		(8,914)			(8,914)
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of warrants (in Shares)			295,985
Issuance of common stock upon exercise of options			$ 1	258			259
Issuance of common stock upon exercise of options (in Shares)			1,417,500
Reclassification of negative additional paid-in capital				7,943		(7,943)
Net loss						(13,031)	(13,031)
Balance at Dec. 31, 2020	$ 13,856	$ 18,962	$ 1			(40,881)	(40,880)
Balance (in Shares) at Dec. 31, 2020	2,692,253	4,942,319	6,393,069
Stock-based compensation				1,854			1,854
Accretion of Series A and Series B redeemable convertible preferred stock	686	1,803		(2,489)			(2,489)
Issuance of common stock upon exercise of options				49			49
Issuance of common stock upon exercise of options (in Shares)			134,541
Vesting of early exercised stock options				163			163
Reclassification of negative additional paid-in capital				2,114		(2,114)
Conversion of preferred stock to common stock upon initial public offering	$ (14,542)	$ (20,765)	$ 1	35,306			35,307
Conversion of preferred stock to common stock upon initial public offering (in Shares)	(2,692,253)	(4,942,319)	11,436,956
Issuance of common stock upon initial public offering, net of issuance costs			$ 1	41,924			41,925
Issuance of common stock upon initial public offering, net of issuance costs (in Shares)			9,775,000
Issuance of underwriter warrants upon initial public offering				2,349			2,349
Reclassification of liability-classified warrants upon initial public offering				3,130			3,130
Conversion of convertible promissory notes and accrued interest upon initial public offering				12,550			12,550
Conversion of convertible promissory notes and accrued interest upon initial public offering (in Shares)			5,015,494
Issuance of common stock for nonemployee services				85			85
Issuance of common stock for nonemployee services (in Shares)			17,000
Beneficial conversion feature upon issuance of convertible promissory note				471			471
Other comprehensive loss					(11)		(11)
Net loss						(21,773)	(21,773)
Balance at Dec. 31, 2021			$ 3	$ 97,506	$ (11)	$ (64,768)	$ 32,730
Balance (in Shares) at Dec. 31, 2021			32,772,060

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (21,773)	$ (13,031)
Depreciation and amortization	74	13
Forgiveness of Paycheck Protection Program loan	(351)
Stock-based compensation for stock grant		267
Stock-based compensation	1,854	446
Accretion of debt discount on convertible promissory notes	772	728
Accrued interest on convertible promissory notes	115	292
Accretion of discount on short-term investments	202
Non-employee services under convertible promissory notes	50	150
Compensation of non-employee services upon issuance of common stock	74
Change in fair value of derivative liability	(121)	(564)
Issuance of convertible promissory notes for services		247
Change in fair value of warrant liability	1,581	1,511
Changes in operating assets and liabilities:
Payroll tax credit	(162)	(384)
Prepaid expenses and other current assets	(802)	(580)
Other assets	(38)	174
Accounts payable	65	231
Other current and noncurrent liabilities	2,277	(166)
Net cash used in operating activities	(16,183)	(10,666)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(565)
Purchases of short-term investments	(23,633)
Maturities of short-term investments	7,499
Net cash used in investing activities	(16,699)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible promissory notes		11,753
Payment of issuance costs		(695)
Proceeds from April 2020 Paycheck Protection Program Loan		351
Repayment of April 2020 Paycheck Protection Program Loan		(351)
Proceeds from May 2020 Paycheck Protection Program Loan		351
Issuance of common stock	76	676
Proceeds from issuance of shares upon Initial Public Offering - net of issuance costs	44,771
Net cash provided by financing activities	44,847	12,085
Net increase in cash and cash equivalents	11,965	1,419
Cash and cash equivalents at beginning of period	5,710	4,291
Cash and cash equivalents at end of period	17,675	5,710
NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of warrants in connection with convertible promissory notes		6
Accretion of Series A redeemable convertible preferred stock	686	2,644
Accretion of Series B redeemable convertible preferred stock	1,803	6,270
Conversion of preferred stock to common stock upon initial public offering	35,307
Reclassification of liability-classified warrants upon initial public offering	3,130
Issuance of underwriter warrants upon initial public offering	2,349
Issuance of convertible promissory notes for completion of non-employee services	500	247
Beneficial conversion feature upon issuance of convertible promissory note	471
Conversion of convertible promissory notes upon initial public offering	12,550
Vesting of common stock issued upon early exercise	136
Issuance of common stock for non-employee services	11
Reclassification of deferred offering costs upon initial public offering	497
Record derivative liability upon issuance of convertible promissory notes		$ 685

Business Organization, Nature o

Business Organization, Nature of Operations	12 Months Ended
	Dec. 31, 2021
Business Organization, Nature of Operations [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	Note 1 – Business Organization, Nature of Operations Movano Inc. (the “Company” or “Movano” or “Our”) was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development-stage and is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medtech and consumer devices. Movano’s mission is to empower and inspire you to live a healthier, happier life. The Company’s solutions are being developed to provide vital health information, including heart rate, HRV, sleep, respiration, temperature, blood oxygen, steps, calories as well as glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback to improve the quality of their life. On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. Operations and activity at the wholly owned subsidiary were not significant for the year ended December 31, 2021. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology. As of December 31, 2021, the Company had not yet completed the development of its product and had not yet recorded any revenues. From February 2020 to December 2020, the Company issued subordinated convertible promissory notes for approximately $11.1 million in net proceeds (See Note 8). Additionally, in May 2020, the Company received a Paycheck Protection Program loan for $0.4 million (See Note 7). The Company’s Registration Statement on Form S-1, as amended (Reg. No. 333-252671), was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on March 23, 2021. The registration statement registered the securities offered in the Company’s initial public offering (“IPO”). In the IPO, the Company sold 9,775,000 shares of common stock at a price to the public of $5.00 per share, including the full exercise of the underwriters’ option to purchase additional shares. The IPO closed on March 25, 2021 and the underwriters exercised their overallotment option as of March 25, 2021, as a result of which the Company raised net proceeds of $44.3 million after deducting $3.3 million in underwriting discounts, commissions, and expenses and $1.3 million in offering expenses paid by the Company. National Securities Corporation (“NSC”) was the underwriter for the IPO, and also received a warrant related to the IPO, which is discussed in Note 11. No portion of the net proceeds from the IPO were used for payments made by the Company to its directors or officers or persons owning ten percent or more of its common stock or to their associates, or to the Company’s affiliates, other than payments in the ordinary course of business to officers for salaries and to nonemployee directors as compensation for board or board committee service. The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through December 31, 2021, the Company has relied primarily on the proceeds from equity offerings to finance its operations. The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying consolidated financial statements in accordance with GAAP. Reclassification Certain reclassifications have been made to prior periods’ consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net loss, total assets or stockholders’ equity (deficit). Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer. Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company classifies all marketable securities for use in current operations, even if the security matures beyond 12 months, and presents them as short-term investments in the consolidated balance sheets. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each consolidated balance sheet date. The Company has classified and accounted for the purchased marketable securities as available-for-sale. After considering the Company’s capital preservation objectives, as well as its liquidity requirements, the Company may sell securities prior to their stated maturities. The Company carries its available-for-sale short-term investments at fair value. The Company reports the unrealized gains and losses, net of taxes, as a component of stockholders’ equity (deficit), except for unrealized losses determined to be credit-related, which are recorded as other income (expense), net in the consolidated statements of operations and comprehensive loss and reports an allowance for credit losses in short-term investments on the consolidated balance sheet, if any. The Company determines any realized gains or losses on the sale of short-term investments on a specific identification method and records such gains and losses as a component of other income (expense), net. Interest earned on cash, cash equivalents, and short-term investments is recorded in interest and other income, net in the accompanying consolidated statements of operations and comprehensive loss and was $0.2 million and an insignificant amount during the years ended December 31, 2021, and 2020, respectively. The Company’s investment policy only allows purchases of high credit quality instruments and provides guidelines on concentrations and credit quality to ensure minimum risk of loss. The Company evaluates whether the unrealized loss on available-for-sale short-term investments is the result of the credit worthiness of the securities it held, or other non-credit-related factors such as liquidity by reviewing a number of factors such as the implied yield of the corporate note based on the market price, the nature of the invested entity’s business or industry, market capitalization relative to debt, changes in credit ratings, and the market prices of the instruments subsequent to the period end. Concentrations of Credit Risk, Credit Losses and Other Risks and Uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and short-term investments. The Company’s cash, cash equivalents, and short-term investments are held by financial institutions that management believes are of high credit quality. The Company’s investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as U.S. government obligations, money market instruments and funds, corporate bonds, commercial paper, and asset-backed securities and places restrictions on maturities and concentrations by type and issuer. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, corporate issuers, and other financial instruments, to the extent recorded in the consolidated balance sheets. The Company is exposed to credit losses primarily through its available-for-sale debt securities. The Company’s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the novel coronavirus (COVID-19) pandemic and determined that the estimate of credit losses was not significantly impacted. The adoption of the guidance did not have a material impact on the consolidated financial statements and related disclosures and there was no allowance for losses on available-for-sale debt securities which were attributable to credit risk for the year ended December 31, 2021. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO within additional paid-in capital upon the effective date of the IPO. As of December 31, 2021 and 2020, offering costs of approximately $0 and $0.5 million were capitalized, respectively. Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company’s product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2021 and 2020, no development costs were capitalized. Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Paycheck Protection Program Loan The Company accounted for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan remained recorded as a liability until the Company was legally released from the liability. The amount that was ultimately forgiven by the lender was recognized in the consolidated statement of operations and comprehensive loss as a gain on extinguishment. Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time. Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below fair value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the consolidated balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method. Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company would have been required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO had been consummated prior to April 1, 2021, or an extension or waiver was obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock became redeemable due to the passage of time, the Company considered the preferred stock to be redeemable as of April 1, 2021. The Company recorded the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the consolidated balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted into 11,436,956 shares of common stock. Comprehensive Loss Comprehensive loss is the change in stockholders’ equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company’s other comprehensive loss is comprised of unrealized gains and losses on investments in available-for-sale securities. Research and Development Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company’s behalf. Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, any changes to deferred tax assets or liabilities resulted in no provision or benefit from income taxes during the years ended December 31, 2021 and 2020. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740 In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recently Issued Accounting Pronouncements – Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases The Company will adopt the new standard effective January 1, 2022 using the modified retrospective transition approach and will not recast prior periods. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements and related disclosures and cannot conclude as to the anticipated impact on the consolidated financial statements and related disclosures at this time. As permitted by the standard, the Company will elect the transition practical expedient package, which among other things, allows the carryforward of historical lease classifications. Accordingly,

Fair value measurements

Fair value measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	Note 3 – FAIR VALUE MEASUREMENTS Financial assets and liabilities are recorded at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The Company measures its cash equivalents, short-term investments and derivative financial instruments at fair value. The Company classifies its cash equivalents and short-term investments within Level 1 or Level 2 because the Company values these investments using quoted market prices or alternative pricing sources and models utilizing market observable inputs. The fair value of the Company’s Level 1 financial assets is based on quoted market prices of the identical underlying security. The fair value of the Company’s Level 2 financial assets is based on inputs that are directly or indirectly observable in the market, including the readily-available pricing sources for the identical underlying security that may not be actively traded. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. At December 31, 2020, the warrants related to the Series A preferred stock issuance, the Series B preferred stock issuance, the convertible promissory notes and the derivative liability related to the issuance of convertible promissory notes are classified within Level 3 of the valuation hierarchy. The instruments are not present at December 31, 2021 in light of accounting ramifications of the IPO, which are discussed further in Note 8 and Note 11. The carrying amounts of prepaid expenses, payroll tax credit, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these instruments. Based upon interest rates currently available to the Company for debt with similar terms, the carrying values of the Company’s convertible promissory notes and Paycheck Protection Program Loan are approximately equal to their fair values. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in thousands). December 31, 2021 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 16,830 $ 16,830 $ — $ — Total cash equivalents $ 16,830 $ 16,830 $ — $ — Short-term investments: Certificates of deposit $ 250 $ — $ 250 $ — Commercial paper 2,210 — 2,210 — Corporate notes 12,024 — 12,024 — Municipal bonds 1,437 — 1,437 — Total short-term investments $ 15,921 $ — $ 15,921 $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Cash equivalents – money market funds $ 5,181 $ 5,181 $ — $ — Warrant liability $ 1,549 $ — $ — $ 1,549 Derivative liability $ 121 $ — $ — $ 121

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	Note 4 – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash, cash equivalents and short-term investments consist of the following (in thousands): December 31, 2021 2020 Cash and cash equivalents: Cash $ 845 $ 529 Money market funds 16,830 5,181 Total cash and cash equivalents $ 17,675 $ 5,710 Short-term investments: Certificates of deposit $ 250 $ — Commercial paper 2,210 — Corporate notes 12,024 — Municipal bonds 1,437 — Total short-term investments $ 15,921 $ — The contractual maturities of short-term investments classified as available-for-sale as of December 31, 2021 were as follows (in thousands): December 31, 2021 Due within one year $ 15,921 Due after one year through five years — Total $ 15,921 The following table summarizes the unrealized gains and losses related to short-term investments classified as available-for-sale on the Company’s consolidated balance sheet (in thousands): December 31, 2021 Amortized Gross Gross Aggregate Short-term investments: Certificates of deposit $ 250 $ — $ — $ 250 Commercial paper 2,210 — — 2,210 Corporate notes 12,035 — (11 ) 12,024 Municipal bonds 1.437 — — 1,437 Total short-term investments $ 15,932 $ — $ (11 ) $ 15,921 As of December 31, 2021, the gross unrealized loss on available-for-sale short-term investments was immaterial and there were no expected credit losses related to the Company’s available-for-sale debt securities. The Company has determined that all unrealized losses are temporary. As of December 31, 2021, no allowance for credit losses in short-term investments was recorded. No sales of available-for-sale short-term investments occurred during the year ended December 31, 2021.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 5 – Property and Equipment Property and equipment, net, as of December 31, 2021 and 2020, consisted of the following (in thousands): December 31, 2021 2020 Office equipment and furniture $ 237 $ 43 Software 115 — Test equipment 278 22 Total property and equipment 630 65 Less: accumulated depreciation (101 ) (27 ) Total property and equipment, net $ 529 $ 38 Total depreciation and amortization expense related to property and equipment for the years ended December 31, 2021 and 2020 was approximately $74,000 and $13,000, respectively.

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2021
Other Current Liabilities [Abstract]
OTHER CURRENT LIABILITIES	Note 6 – Other Current Liabilities Other current liabilities as of December 31, 2021 and 2020 consisted of the following (in thousands): December 31, 2021 2020 Accrued research and development $ 289 $ 197 Accrued compensation 2,211 184 Accrued vacation 276 192 Other 131 93 $ 2,907 $ 666

Paycheck Protection Program Loa

Paycheck Protection Program Loan	12 Months Ended
	Dec. 31, 2021
Paycheck Protection Program Loan [Abstract]
PAYCHECK PROTECTION PROGRAM LOAN	NOTE 7 – PAYCHECK PROTECTION PROGRAM LOAN The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 23, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000 under the PPP (the “PPP Loan”). The interest rate on the PPP Loan was 1.00% and the term was two years, with a deferral of payments for ten months from the date of origination. On May 7, 2020, the Company elected to repay the PPP loan in full until further guidance was provided by the SBA on the loan origination and eligibility requirements. On May 27, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000, with all other terms the same as the prior loan. Beginning eleven months from the date of the PPP Loan, the Company was required to make monthly payments of principal and interest. The promissory note evidencing the PPP Loan contained customary events of default relating to, among other things, payment defaults or breaching the terms of the PPP Loan documents. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment against the Company. The PPP Loan was repayable at any time by the Company without prepayment penalties. Funds from the PPP Loan could be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations, if those debt obligations were incurred before February 15, 2020. The Company used the entire PPP Loan amount for qualifying expenses. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for qualifying expenses. On May 28, 2021, the Company received full loan forgiveness for obligations related to the PPP loan. The Company accounted for the PPP loan as debt, and the loan forgiveness was accounted for as a debt extinguishment. The amount of loan and interest forgiven is recognized as a gain upon debt extinguishment and is reported in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2021.

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 8 – CONVERTIBLE PROMISSORY NOTES On various dates between February 2020 and December 2020, the Company received total proceeds of approximately $11.8 million from the issuance of subordinated convertible promissory notes (“Convertible Notes”) to investors. The Convertible Notes accrued interest at 4% per year and the principal balance of the Convertible Notes, plus all accrued interest would have been due on February 28, 2022 (the Maturity Date). The Convertible Notes were convertible upon the occurrence of certain events, including upon a change in control or a next equity financing. The conversion features are described as follows: Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing. Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing. As part of the Convertible Note financing, the Company agreed to issue subordinated convertible promissory notes to nonemployees in exchange for services totaling $747,000. As of December 31, 2020, Convertible Notes totaling approximately $247,000 were issued to nonemployees in exchange for services. As of December 31, 2020, future services of $500,000 of the original $747,000 had not been fully completed. A portion of those services that had been completed were recorded as a component of other noncurrent liabilities of $150,000 on the consolidated balance sheet at December 31, 2020. During the three months ended March 31, 2021, additional nonemployee services of $50,000 were completed, which were recorded as a component of other noncurrent liabilities. In connection with the IPO, a Convertible Note for $500,000 was issued for nonemployee services and the $300,000 of the nonemployee services that remained to be completed was recorded in prepaid assets and other current expenses on the consolidated balance sheet. The Company calculated a BCF of approximately $500,000 upon the issuance of this Convertible Note. In connection with the Convertible Notes, the Company issued 10,000 and 204,500 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and are initially exercisable into common stock at $2.97 per share. (See Note 11 – Common Stock Warrants for fair value computation and discussion of the change in the exercise price). During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Issuance costs and commissions to brokers to obtain the Convertible Notes were recorded as a debt discount in the amount of approximately $83,000 and $612,000, respectively. The Company determined that the terms that would result in Convertible Notes automatically converting at (i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative. Accordingly, subsequent changes in the fair value of these redemption features are measured at each reporting period and recognized in the consolidated statement of operations and comprehensive loss. The sum of the fair value of the warrants, the fair value of the embedded redemption derivative liability, issuance costs, BCF and commission payments for the Convertible Notes were recorded as debt discounts to be amortized to interest expense over the respective term using the effective interest method. During the years ended December 31, 2021 and 2020, the Company recognized interest expense of approximately $0.8 million and $0.7 million from the accretion of those debt discounts, respectively. The Convertible Notes automatically converted upon the closing of the IPO at the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to the closing of the IPO. The outstanding principal ($12.5 million) and interest due ($0.4 million) under the Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock at the implied per share conversion of $2.5736. The carrying value of the Convertible Notes was credited to common stock and additional paid-in capital on the consolidated balance sheet. The remaining unamortized discount of $0.4 million was recorded to additional paid-in capital and no gain or loss was recognized on the conversion. The remaining unamortized discount related to the BCF of $0.5 million was recognized immediately as interest expense in the consolidated statement of operations and comprehensive loss. Derivative Liability As described above, the redemption provisions embedded in the Convertible Notes required bifurcation and measurement at fair value as a derivative. The fair value of the Convertible Note embedded redemption derivative liability was calculated by determining the value of the debt component of the Convertible Notes at various conversion or maturity dates using a Probability Weighted Expected Return valuation method. The fair value calculation placed greater probability on the occurrence of the conversion or the maturity date scenario, with little or no weight given to other scenarios. The fair value of the embedded redemption derivative liability is significantly influenced by the discount rate, the remaining term to maturity and the Company’s assumptions related to the probability of a qualified financing or no financing prior to maturity. The Financing Date is the estimated date of an automatic conversion as the result of a Next Qualified Equity Financing or an IPO. The Company estimated the fair value of the embedded redemption derivative liability using the following weighed average assumptions as of December 31, 2020: Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 1.68% to 11.67% N/A The embedded redemption derivative liability no longer had significant value as of the date of the Company’s IPO since the conversion of the Convertible Notes occurred via a redemption feature that was not bifurcated as a derivative. Upon the conversion of the Convertible Notes at the IPO, the Company recorded a final change in the fair value of the derivative liability of $0.1 million in the consolidated statement of operations and comprehensive loss, and the derivative liability was extinguished. The changes in the fair value of the derivative liability for the year ended December 31, 2021 and 2020 were as follows: December 31, Fair Value at Change in December 31, Derivative liability $ 121 — (121 ) $ — December 31, Fair Value at Change in December 31, Derivative liability $ — 685 (564 ) $ 121

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Redeemable Convertible Preferred Stock Disclosure [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	Note 9 – REDEEMABLE Convertible Preferred Stock On March 28, 2019, the Company’s Second Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) increased the number of shares of common stock the Company is authorized to issue to 22,069,652; (ii) increased the number of shares of preferred stock the Company was authorized to issue to 7,930,348, of which 2,692,253 shares were designated as Series A preferred stock and 5,238,095 shares were designated as Series B preferred stock; (iii) amended and set a fixed conversion price of Series A preferred stock to $1.40; and (iv) extended the IPO Commitment Date from April 1, 2020 to no later than March 31, 2021. The Company assessed the accounting treatment of the amendment of the Certificate of Incorporation related to the Series A preferred stock and determined that the amendment is a modification for accounting purposes. After considering the nature of the changes as a result of the amendment, the Company determined the modification of the Series A preferred stock did not have a significant impact on the consolidated financial statements. The Series B preferred stock was measured and recorded at the transaction price net of issuance costs, resulting in an initial value of $9.3 million. The accretion to the carrying value of the Series B preferred stock was recorded as a charge to additional paid in capital. The accumulated accretion as of the IPO date was $11.5 million, which resulted in an adjusted Series B preferred stock carrying value of $20.8 million. The accretion to the carrying value of the Series A preferred stock was recorded as a charge to additional paid-in capital. The accumulated accretion as of the IPO date was $8.2 million, which resulted in an adjusted Series A preferred stock carrying value of $14.5 million. Upon the IPO, the redeemable convertible preferred stock converted in to 11,436,956 shares of common stock and no shares of redeemable convertible preferred stock remain outstanding as of December 31, 2021. On March 24, 2021, the Company’s Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
COMMON STOCK	Note 10 – Common Stock As of December 31, 2021 and 2020, the Company was authorized to issue 75,000,000 and 22,069,652 shares of common stock with a par value of $0.0001 per share, and 32,772,060 and 6,393,069 shares were issued and outstanding, respectively. Conversion of Redeemable Convertible Preferred Stock In connection with the closing of the IPO, on March 25, 2021, the outstanding shares of the Company’s Series A and Series B redeemable convertible preferred stock were converted into 11,436,956 shares of the Company’s common stock. Conversion of Convertible Notes In connection with the funding of the IPO, on March 25, 2021, the principal and interest due under the Company’s Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock. Third Amended and Restated Certificate of Incorporation In connection with the IPO, the Third Amended and Restated Certificate of Incorporation became effective and authorized 75,000,000 shares of common stock at par value of $0.0001 per share. Dividends may be declared and paid on the common stock when and if determined by the Board of Directors. Upon liquidation, each common stockholder is entitled to receive an equal portion of the distribution. Each holder of common stock will have one vote in respect of each share of common stock held. The rights and privileges listed above will be subject to preferential rights of any then outstanding shares of preferred stock. At the IPO date, the Company issued 17,000 shares of common stock for nonemployee services valued at $85,000. Common stock reserved for future issuance at December 31, 2021 is summarized as follows: Warrants to purchase common stock 1,938,143 Stock options outstanding 5,592,137 Stock options available for future grants under the 2019 Plan 115,822 Total 7,646,102 Restricted Stock Purchase Agreements In 2018, 400,000 shares of common stock were issued to the Company’s founder at inception pursuant to a Restricted Stock Purchase Agreement. The Restricted Stock Purchase Agreement stipulates that in the event of the voluntary or involuntary termination of the Company’s founder’s continuous service status for any reason (including death or disability), with or without cause, the Company or its assignees(s) shall have an option (“Repurchase Option”) to repurchase all or any portion of the shares held by the Purchaser as of the termination date which have not yet been released from the Company’s Repurchase Option at the original purchase price of $0.0125 per share. Shares are to be released from the Repurchase Option over four years. The initial 12/48ths of the shares were released on January 30, 2019, and an additional 1/48th of the shares are being released monthly thereafter. As of December 31, 2021 and 2020, 8,333 and 108,333 of the shares issued to the Company’s founder remain subject to the Repurchase Option, respectively. These shares were originally purchased by the Company’s founder at $0.0125 per share. In 2018, 3,640,000 shares of common stock were also issued pursuant to a Restricted Stock Purchase Agreement. The holders of these shares are considered related parties of the Company because the holders are directly related either to the founder or to the former legal counsel of the Company. The same terms described above apply to these issuances. As of December 31, 2021 and 2020, 75,833 and 985,834 of the shares issued to these holders remain subject to the Repurchase Option, respectively. These shares were originally purchased by the holders at $0.0125 per share. Early Exercised Stock Option Liability During the year ended December 31, 2021, 50,000 shares of common stock were issued upon the early exercise of common stock options. The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. During the year ended December 31, 2020, 890,356 shares of common stock were issued upon the early exercise of common stock options. As of December 31, 2021 and 2020, the Company has recorded a repurchase liability for approximately $281,000 and $417,000 for 567,397 and 856,814 shares that remain unvested, respectively. The weighted average remaining vesting period at December 31, 2021 is approximately 1.99 years.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2021
Common Stock Warrants [Abstract]
COMMON STOCK WARRANTS	Note 11 – Common Stock Warrants Preferred A Placement Warrants On February 22, 2018, the Company entered into an agreement with NSC, pursuant to which the Company engaged NSC as the Company’s exclusive financial advisor and placement agent in connection with an offering or series of offerings of Company securities. Specifically, NSC was the placement agent in connection with the sale of its Series A preferred stock. In connection with the closing of Series A preferred stock offering, the Company issued warrants (“Preferred A Placement Warrants”) to purchase a total of 133,648 shares of its common stock to NSC on March 14, 2018 and April 23, 2018. On June 1, 2018, the Preferred A Placement Warrants were reassigned among NSC and three individuals at Liquid Venture Partners (“LVP”). The Preferred A Placement Warrants have a term of five years and the exercise price was initially equal to the conversion price of Series A preferred stock upon its conversion. The Preferred A Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series A preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 1,336,485 shares of Series A preferred stock (the “Preferred A Adjustment Provision”). The Second Amended and Restated Certificate of Incorporation that was approved on March 28, 2019 amended and fixed the conversion price of the Series A preferred stock at $1.40. As a result, on August 28, 2019, the Company elected to amend and reissue the Preferred A Placement Warrants, thereby reducing the exercise price to $1.40 and increasing the number of warrant shares by 109,200 to a total of 242,847 warrant shares. In connection with the IPO, pursuant to the Preferred A Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred A Placement Warrants settled, resulting in an additional 50,195 shares of common stock. Preferred A Lead Investor Warrants During February 2021, a total of 52,500 warrants for common stock were issued to advisors to the Company at a weighted average exercise price of $0.0125 per share. The resulting fair value of the warrants for common stock is not significant. Preferred B Placement Warrants On April 16, 2019, in connection with the Series B preferred stock offering, the Company issued warrants (“Preferred B Placement Warrants”) to purchase 414,270 shares of its common stock to NSC, Newbridge Securities Corporation, and five individuals at LVP. The Preferred B Placement Warrants have a term of five years and their exercise price is equal to $2.10, the conversion price of Series B preferred stock. The Preferred B Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series B preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 4,142,270 shares of Series B preferred stock (the “Preferred B Adjustment Provision”). In connection with the IPO, pursuant to the Preferred B Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred B Placement Warrants settled, resulting in an additional 49,528 shares of common stock. Convertible Note Placement Warrants In connection with the Convertible Notes, the Company issued 10,000 and 204,050 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and were initially exercisable into common stock at $2.97 per share with the warrants ultimately being exercisable into common stock at the final Conversion Price of the Convertible Notes. When the Convertible Notes converted at the IPO date as described in Note 8, the exercise price of the warrants was adjusted to equal the Conversion Price, which is $2.57. During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Underwriter Warrants In connection with the IPO, the Company issued the underwriter a warrant to purchase shares of common stock equal to 9.79% of the shares of common stock sold in the IPO or 956,973 shares. The warrant is exercisable at $6.00 per share and has a 5-year term. Additionally, the underwriter has contractually agreed that it will not sell, transfer, assign, pledge, or hypothecate this warrant or the securities underlying this warrant, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of this warrant or the underlying securities for a period of 540 days (approximately 18 months) from the IPO. The following is a summary of the Company’s warrant activity for the years ended December 31, 2021 and 2020: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143 Warrant Issuance Issuance Exercise Price Outstanding, December 31, 2019 Granted Exercised Canceled/ Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2020 Expiration Consulting Warrants February 2018 $ 0.0125 303,000 — (295,985 ) (7,015 ) — — February 2023 Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — — 242,847 March and April 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — — 414,270 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 — 214,050 — — — 214,050 August 2025 960,117 214,050 (295,985 ) (7,015 ) 871,167 Warrants Classified as Liabilities Preferred A Placement Warrants and Preferred B Placement Warrants The Preferred A Placement Warrants and Preferred B Placement Warrants were initially classified as a derivative liability because their variable terms did not qualify these as being indexed to the Company’s own common stock and were initially measured at fair value on a recurring basis. As a result of the conversion of the Preferred Stock into common stock in connection with the IPO, and the related impact of the Preferred A Adjustment Provision and the Preferred B Adjustment Provision, the number of warrant shares that are convertible is no longer variable. Accordingly, the Preferred A Placement Warrants and Preferred B Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Thus, the Preferred A Placement Warrants and the Preferred B Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Convertible Notes Placement Warrants The Convertible Notes Placement Warrants were classified as a derivative liability because the exercise price was variable, thus these did not qualify as being indexed to the Company’s own common stock and were measured at fair value on a recurring basis. As a result of the conversion of the Convertible Notes into common stock in connection with the IPO, the exercise price is no longer variable. Accordingly, the Convertible Notes Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Thus, the Convertible Notes Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Estimated Fair Value of Outstanding Warrants Classified as Liabilities The estimated fair value of outstanding warrants classified as liabilities is determined at each consolidated balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent consolidated balance sheet date is recorded in the consolidated statements of operations and comprehensive loss as a change in fair value of warrant liability. There were no warrants classified as liabilities outstanding as of December 31, 2021. The changes in fair value of the outstanding warrants classified as liabilities for the year ended December 31, 2021 were as follows (in thousands): Warrant Issuance Warrant liability, Fair value of Fair value of Change in fair Reclassified to Warrant liability, Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) — Convertible Notes Placement Warrants 323 — — 206 (529 ) — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ — The changes in fair value of the warrant liability for the year ended December 31, 2020 were as follows (in thousands): Warrant Issuance Warrant liability, Fair value of Fair value of Change in fair Warrant liability, Preferred A Placement Warrants $ 12 $ — $ — $ 506 $ 518 Preferred B Placement Warrants 20 — — 688 708 Convertible Notes Placement Warrants — 6 — 317 323 $ 32 $ 6 $ — $ 1,511 $ 1,549 The fair values of the outstanding warrants accounted for as liabilities at the IPO date are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants — % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants — % 52.28 % 0.82 % 4.4 years Upon the conversion of the redeemable convertible preferred stock and the Convertible Notes into common stock at the IPO date, the estimated fair value of the outstanding warrants accounted for as liabilities of $3.1 million was reclassified to additional paid-in capital. The fair values of the outstanding warrants accounted for as liabilities at December 31, 2020 are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions - December 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 67.75 % 0.13 % 2.2 years Preferred B Placement Warrants — % 55.76 % 0.17 % 3.3 years Convertible Note Placement Warrants — % 52.93 % 0.36 % 4.7 years Warrants Classified as Equity Certain warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing model with the following assumptions. The fair value as determined at the issuance date is recorded as an issuance cost of the related stock. Those warrants and the assumptions used to calculate the fair value at issuance are as follows for the warrants issued during the year ended December 31, 2021. There were no warrants issued during the year ended December 31, 2020. Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 — % 52.58 % 0.82 % 5.0 years

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	Note 12 – Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan (“2019 Plan”) administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4,000,000 shares of the Company’s common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10% or greater stockholders must have an exercise price at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. On September 30, 2020, the Board approved an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 4,000,000 to 4,500,000. On December 7, 2020, the Board approved an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 4,500,000 to 6,000,000. In connection with the closing of the IPO, effective as of March 25, 2021 the 2019 Plan was amended and restated as a result of which the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan was increased from 6,000,000 to 7,400,000. As of December 31, 2021, the Company had 115,822 shares available for future grant under the 2019 Plan. Stock Options Stock option activity for the years ended December 31, 2021 and 2020 was as follows (in thousands, except share, per share, and remaining life data): Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Value Outstanding at December 31, 2019 3,027,200 $ 0.41 9.6 years $ — Granted 1,732,478 $ 0.92 Exercised (1,417,500 ) $ 0.48 Cancelled (154,167 ) $ 0.38 Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 2,684,500 $ 4.05 Exercised (134,541) $ 0.56 Cancelled (145,833) $ 0.59 Outstanding at December 31, 2021 5,592,137 $ 2.29 8.6 years $ 9,912 Exercisable as of December 31, 2021 2,046,994 $ 0.58 7.9 years $ 6,604 Vested and expected to vest as of December 31, 2021 5,541,937 $ 2.30 8.7 years $ 9,741 The weighted-average grant date fair value of options granted during the years ended December 31, 2021, and 2020 was $2.54 and $1.78 per share, respectively. During the years ended December 31, 2021 and 2020, 134,531 and 1,417,500 options were exercised for proceeds of $0.1 million and $0.7 million, respectively. The fair value of the 839,380 and 1,079,120 options that vested during the years ended December 31, 2021 and 2020 was approximately $0.7 million and $0.4 million, respectively. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the years ended December 31, 2021 and 2020. Year Ended 2021 2020 Dividend yield — % — % Expected volatility 66.38 % 68.23 % Risk-free interest rate 0.93 % 0.50 % Expected life 6.05 years 5.89 years Dividend Rate Expected Volatility Risk-Free Interest Rate Expected Term Forfeiture Rate The Company has recorded stock-based compensation expense for the years ended December 31, 2021 and 2020 related to the issuance of stock option awards to employees and nonemployees in the consolidated statement of operations and comprehensive loss as follows: Year Ended 2021 2020 Research and development $ 716 $ 86 General and administrative 1,138 627 $ 1,854 $ 713 As of December 31, 2021, unamortized compensation expense related to unvested stock options was approximately $7.8 million, which is expected to be recognized over a weighted average period of 2.96 years. 2021 Employment Inducement Plan On September 15, 2021 the Company’s Board adopted the Movano, Inc. 2021 Inducement Award Plan (the “Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (“Rule 5635(c)(4)”). In accordance with Rule 5635(c)(4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company’s Board, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee’s entering into employment with the Company or its subsidiary. An aggregate of 2,000,000 shares of the Company’s common stock have been reserved for issuance under the Inducement Plan. The Company will continue to grant awards under the 2019 Plan pursuant to the terms thereof. No awards have been issued under the Inducement Plan during the year ended December 31, 2021.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 13 – Commitments and Contingencies Operating Leases As of December 31, 2021, the Company had one office lease. Another lease, for facility space in Dublin, California expired in September 2021. On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease commenced on May 14, 2021 when the improvements were completed by the landlord and the Company had access to the facility. The lease term is 40 months, and the base rent is approximately $14,000 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid a security deposit of approximately $47,000. Future minimum lease payments for this new corporate office space lease are as follows as of December 31, 2021 (in thousands): 2022 $ 173 2023 179 2024 138 Total $ 490 Rent expense for the years ended December 31, 2021 and 2020 was $154,000 and $99,000, respectively. Litigation From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company’s business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of December 31, 2021.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14 – INCOME TAXES For the years ended December 31, 2021 and 2020, no U.S. provision or benefit for income taxes was recorded and an insignificant amount of Ireland provision for income taxes for the year ended December 31, 2021 was offset by credits. The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal rate as follows: Year Ended December 31, 2021 2020 US federal provision (benefit) At Statutory rate 21 % 21 % Valuation allowance (18 %) (17 %) Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes (3 %) (3 %) Other 1 % (1 %) Effective tax rate — — The Company did not record any income tax expense or benefit as the Company incurred losses in all periods presented. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2021 and 2020 are as follows (in thousands): 2021 2020 Gross deferred tax assets: Net operating loss carryforwards $ 7,765 $ 4,523 Research and development credit carryforward 712 367 Accrued bonus 403 — Stock-based compensation 72 74 Other 76 27 Total gross deferred tax assets 9,029 4,991 Less valuation allowance (9,022 ) (4,988 ) Total net deferred tax assets 7 3 Deferred tax liabilities: Property and equipment (7 ) (3 ) Total deferred tax liabilities (7 ) (3 ) Net deferred tax assets $ — $ — During 2021 and 2020, the Company has maintained a valuation allowance against the net deferred tax assets due to the uncertainty surrounding the realization of those assets. The Company periodically evaluates the recoverability of the deferred tax assets and, when it is determined to be more-likely-than-not that the deferred tax assets are realizable, the valuation allowance is reduced. The valuation allowance increased by approximately $4,134,000 and $2,326,000 during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, the Company has federal net operating loss carryforwards of approximately $37.5 million and $21.5 million, respectively, all of which do not expire. The net operating loss carryforwards may be available to offset future taxable income for income tax purposes. As of December 31, 2021 and 2020, the Company has federal research and development (“R&D”) credit carryforwards of approximately $560,000 and $238,000, respectively. The federal R&D credits begin to expire in 2039. As of December 31, 2021 and 2020, the Company has California R&D credit carryforwards of approximately $640,000 and $418,000, respectively. The California R&D credits do not expire. The Internal Revenue Code imposes limitations on a corporation’s ability to utilize net operating loss (“NOL”) and credit carryovers if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. If an ownership change has occurred, or were to occur, utilization of the Company’s NOLs and credit carryovers could be restricted. The Company accounts for uncertainty in income taxes pursuant to the relevant authoritative guidance. The guidance clarified the recognition of tax positions taken, or expected to be taken, on a tax return. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. No liability related to uncertain tax positions is recorded in the financial statements. The Company files income tax returns in the U.S. federal jurisdiction and in California. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and California state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits. Total gross unrecognized tax benefit liabilities as of December 31, 2021 and 2020 were approximately $487,000 and $289,000, respectively, related to Federal and California R&D credits. As of December 31, 2021 and 2020, the Company had no unrecognized tax benefits, which, if recognized would affect the Company’s effective tax rate due to the full valuation allowance. The Company’s policy is to classify interest and penalties related to unrecognized tax benefits as part of the income tax provision (benefit) in the statements of operations and comprehensive loss. The Company had no accrued interest and penalties related to unrecognized tax benefits as of December 31, 2021. The following is a rollforward of the total gross unrecognized tax benefits for the years ended December 31, 2021 and 2020 (in thousands): Year Ended December 31, 2021 2020 Beginning Balance 289 $ 164 Gross Increases - Tax Position in Current Period 198 125 Ending Balance $ 487 $ 289 All tax years remain subject to examination by the U.S. federal and state taxing authorities due to the Company’s net operating losses and R&D credit carry carryforwards.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	Note 15 – NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table computes the computation of the basic and diluted net loss per share attributable to common stockholders during the years ended December 31, 2021 and 2020 is as follows (in thousands, except share and per share data): Year Ended December 31, 2021 2020 Numerator: Net loss $ (21,773 ) $ (13,031 ) Accretion and dividends on redeemable convertible preferred stock (2,489 ) (8,914 ) Net loss attributable to common stockholders $ (24,262 ) $ (21,945 ) Denominator: Weighted-average common shares outstanding 26,298,032 3,201,430 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (6.85 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2021 and 2020 because including them would have been antidilutive are as follows: December 31, 2021 2020 Shares of redeemable convertible preferred stock — 11,299,425 Non-vested shares under restricted stock grants 84,167 1,094,167 Shares related to convertible promissory notes — 4,656,918 Shares subject to options to purchase common stock 5,541,937 3,137,811 Shares subject to warrants to purchase common stock 1,938,143 871,167 Total 7,564,247 21,059,488 For the years ended December 31, 2021 and 2020, performance based option awards for 50,200 shares of common stock, respectively, are not included in in the table above or considered in the calculation of diluted earnings per share until the performance conditions of the option award are considered probable by the Company.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 16 – Subsequent Events On February 14, 2022, pursuant to the Inducement Plan, the Company granted inducement stock option awards covering a total of 720,000 shares of common stock to non-executive employees. The stock options were granted at an exercise price of $2.60 per share, which is equal to the closing price of Movano common stock on the date of grant. The stock options vest as follows: one-fourth vests on the first anniversary of the grant date and the balance vests in 36 equal monthly installments thereafter. The awards were approved by the independent Compensation Committee of the Company’s Board of Directors and were granted as an inducement material to the new employees’ entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4).

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying consolidated financial statements in accordance with GAAP.
Reclassification	Reclassification Certain reclassifications have been made to prior periods’ consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net loss, total assets or stockholders’ equity (deficit).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer.
Cash, Cash Equivalents and Short-term Investments	Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company classifies all marketable securities for use in current operations, even if the security matures beyond 12 months, and presents them as short-term investments in the consolidated balance sheets. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each consolidated balance sheet date. The Company has classified and accounted for the purchased marketable securities as available-for-sale. After considering the Company’s capital preservation objectives, as well as its liquidity requirements, the Company may sell securities prior to their stated maturities. The Company carries its available-for-sale short-term investments at fair value. The Company reports the unrealized gains and losses, net of taxes, as a component of stockholders’ equity (deficit), except for unrealized losses determined to be credit-related, which are recorded as other income (expense), net in the consolidated statements of operations and comprehensive loss and reports an allowance for credit losses in short-term investments on the consolidated balance sheet, if any. The Company determines any realized gains or losses on the sale of short-term investments on a specific identification method and records such gains and losses as a component of other income (expense), net. Interest earned on cash, cash equivalents, and short-term investments is recorded in interest and other income, net in the accompanying consolidated statements of operations and comprehensive loss and was $0.2 million and an insignificant amount during the years ended December 31, 2021, and 2020, respectively. The Company’s investment policy only allows purchases of high credit quality instruments and provides guidelines on concentrations and credit quality to ensure minimum risk of loss. The Company evaluates whether the unrealized loss on available-for-sale short-term investments is the result of the credit worthiness of the securities it held, or other non-credit-related factors such as liquidity by reviewing a number of factors such as the implied yield of the corporate note based on the market price, the nature of the invested entity’s business or industry, market capitalization relative to debt, changes in credit ratings, and the market prices of the instruments subsequent to the period end.
Concentrations of Credit Risk, Credit Losses and Other Risks and Uncertainties	Concentrations of Credit Risk, Credit Losses and Other Risks and Uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and short-term investments. The Company’s cash, cash equivalents, and short-term investments are held by financial institutions that management believes are of high credit quality. The Company’s investment policy limits investments to fixed income securities denominated and payable in U.S. dollars such as U.S. government obligations, money market instruments and funds, corporate bonds, commercial paper, and asset-backed securities and places restrictions on maturities and concentrations by type and issuer. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents, corporate issuers, and other financial instruments, to the extent recorded in the consolidated balance sheets. The Company is exposed to credit losses primarily through its available-for-sale debt securities. The Company’s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers’ credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers’ current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the novel coronavirus (COVID-19) pandemic and determined that the estimate of credit losses was not significantly impacted. The adoption of the guidance did not have a material impact on the consolidated financial statements and related disclosures and there was no allowance for losses on available-for-sale debt securities which were attributable to credit risk for the year ended December 31, 2021. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO within additional paid-in capital upon the effective date of the IPO. As of December 31, 2021 and 2020, offering costs of approximately $0 and $0.5 million were capitalized, respectively.
Software Development Costs	Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company’s product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2021 and 2020, no development costs were capitalized.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount.
Paycheck Protection Program Loan	Paycheck Protection Program Loan The Company accounted for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan remained recorded as a liability until the Company was legally released from the liability. The amount that was ultimately forgiven by the lender was recognized in the consolidated statement of operations and comprehensive loss as a gain on extinguishment.
Convertible Financial Instruments	Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time.
Beneficial Conversion Feature	Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below fair value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the consolidated balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company would have been required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO had been consummated prior to April 1, 2021, or an extension or waiver was obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock became redeemable due to the passage of time, the Company considered the preferred stock to be redeemable as of April 1, 2021. The Company recorded the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the consolidated balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted into 11,436,956 shares of common stock.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is the change in stockholders’ equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company’s other comprehensive loss is comprised of unrealized gains and losses on investments in available-for-sale securities.
Research and Development	Research and Development Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company’s behalf.
Stock-Based Compensation	Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur.
Early Exercised Stock Option Liability	Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, any changes to deferred tax assets or liabilities resulted in no provision or benefit from income taxes during the years ended December 31, 2021 and 2020. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update 2019-12, Income Taxes (Topic 740 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements – Not Yet Adopted In February 2016, the FASB issued ASU No. 2016-02, Leases The Company will adopt the new standard effective January 1, 2022 using the modified retrospective transition approach and will not recast prior periods. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements and related disclosures and cannot conclude as to the anticipated impact on the consolidated financial statements and related disclosures at this time. As permitted by the standard, the Company will elect the transition practical expedient package, which among other things, allows the carryforward of historical lease classifications. Accordingly,

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities that are measured at fair value	December 31, 2021 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 16,830 $ 16,830 $ — $ — Total cash equivalents $ 16,830 $ 16,830 $ — $ — Short-term investments: Certificates of deposit $ 250 $ — $ 250 $ — Commercial paper 2,210 — 2,210 — Corporate notes 12,024 — 12,024 — Municipal bonds 1,437 — 1,437 — Total short-term investments $ 15,921 $ — $ 15,921 $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Cash equivalents – money market funds $ 5,181 $ 5,181 $ — $ — Warrant liability $ 1,549 $ — $ — $ 1,549 Derivative liability $ 121 $ — $ — $ 121

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Schedule of cash, cash equivalents and short-term investments	December 31, 2021 2020 Cash and cash equivalents: Cash $ 845 $ 529 Money market funds 16,830 5,181 Total cash and cash equivalents $ 17,675 $ 5,710 Short-term investments: Certificates of deposit $ 250 $ — Commercial paper 2,210 — Corporate notes 12,024 — Municipal bonds 1,437 — Total short-term investments $ 15,921 $ —
Schedule of contractual maturities of short-term investments	December 31, 2021 Due within one year $ 15,921 Due after one year through five years — Total $ 15,921
Schedule of unrealized gains and losses related to short-term investments	December 31, 2021 Amortized Gross Gross Aggregate Short-term investments: Certificates of deposit $ 250 $ — $ — $ 250 Commercial paper 2,210 — — 2,210 Corporate notes 12,035 — (11 ) 12,024 Municipal bonds 1.437 — — 1,437 Total short-term investments $ 15,932 $ — $ (11 ) $ 15,921

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, 2021 2020 Office equipment and furniture $ 237 $ 43 Software 115 — Test equipment 278 22 Total property and equipment 630 65 Less: accumulated depreciation (101 ) (27 ) Total property and equipment, net $ 529 $ 38

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Other Current Liabilities [Abstract]
Schedule of other current liabilities	December 31, 2021 2020 Accrued research and development $ 289 $ 197 Accrued compensation 2,211 184 Accrued vacation 276 192 Other 131 93 $ 2,907 $ 666

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of convertible note	Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing. Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.
Schedule of fair value of the embedded redemption derivative liability	Financing Date Maturity Date Probability of Conversion at Financing 80% 20% Expected Term March 2021 February 2022 Conversion Ratio 1.25 N/A Discount Rate 1.68% to 11.67% N/A
Schedule of fair value of the derivative liability	December 31, Fair Value at Change in December 31, Derivative liability $ 121 — (121 ) $ — December 31, Fair Value at Change in December 31, Derivative liability $ — 685 (564 ) $ 121

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of common stock reserved for future issuance	Warrants to purchase common stock 1,938,143 Stock options outstanding 5,592,137 Stock options available for future grants under the 2019 Plan 115,822 Total 7,646,102

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
Schedule of company's warrant activity	Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Settlement Provision Adjustment Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143 Warrant Issuance Issuance Exercise Price Outstanding, December 31, 2019 Granted Exercised Canceled/ Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2020 Expiration Consulting Warrants February 2018 $ 0.0125 303,000 — (295,985 ) (7,015 ) — — February 2023 Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — — 242,847 March and April 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — — 414,270 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 — 214,050 — — — 214,050 August 2025 960,117 214,050 (295,985 ) (7,015 ) 871,167
Schedule of changes in fair value of the warrant liability	Warrant Issuance Warrant liability, Fair value of Fair value of Change in fair Reclassified to Warrant liability, Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) — Convertible Notes Placement Warrants 323 — — 206 (529 ) — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ — Warrant Issuance Warrant liability, Fair value of Fair value of Change in fair Warrant liability, Preferred A Placement Warrants $ 12 $ — $ — $ 506 $ 518 Preferred B Placement Warrants 20 — — 688 708 Convertible Notes Placement Warrants — 6 — 317 323 $ 32 $ 6 $ — $ 1,511 $ 1,549
Schedule of Black-Scholes option pricing model assumptions	Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants — % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants — % 52.28 % 0.82 % 4.4 years Black-Scholes Fair Value Assumptions - December 31, 2020 Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 67.75 % 0.13 % 2.2 years Preferred B Placement Warrants — % 55.76 % 0.17 % 3.3 years Convertible Note Placement Warrants — % 52.93 % 0.36 % 4.7 years
Schedule of fair value at issuance for warrants	Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 — % 52.58 % 0.82 % 5.0 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock option activity	Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Value Outstanding at December 31, 2019 3,027,200 $ 0.41 9.6 years $ — Granted 1,732,478 $ 0.92 Exercised (1,417,500 ) $ 0.48 Cancelled (154,167 ) $ 0.38 Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 2,684,500 $ 4.05 Exercised (134,541) $ 0.56 Cancelled (145,833) $ 0.59 Outstanding at December 31, 2021 5,592,137 $ 2.29 8.6 years $ 9,912 Exercisable as of December 31, 2021 2,046,994 $ 0.58 7.9 years $ 6,604 Vested and expected to vest as of December 31, 2021 5,541,937 $ 2.30 8.7 years $ 9,741
Schedule of weighted average assumptions for fair value of options estimated	Year Ended 2021 2020 Dividend yield — % — % Expected volatility 66.38 % 68.23 % Risk-free interest rate 0.93 % 0.50 % Expected life 6.05 years 5.89 years
Schedule of stock-based compensation expense to employees and non-employees	Year Ended 2021 2020 Research and development $ 716 $ 86 General and administrative 1,138 627 $ 1,854 $ 713

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	2022 $ 173 2023 179 2024 138 Total $ 490

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of the effective tax rate of the company’s provision (benefit) for income taxes differs from the federal rate	Year Ended December 31, 2021 2020 US federal provision (benefit) At Statutory rate 21 % 21 % Valuation allowance (18 %) (17 %) Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes (3 %) (3 %) Other 1 % (1 %) Effective tax rate — —
Schedule of significant components of the company’s deferred tax assets and liabilities	2021 2020 Gross deferred tax assets: Net operating loss carryforwards $ 7,765 $ 4,523 Research and development credit carryforward 712 367 Accrued bonus 403 — Stock-based compensation 72 74 Other 76 27 Total gross deferred tax assets 9,029 4,991 Less valuation allowance (9,022 ) (4,988 ) Total net deferred tax assets 7 3 Deferred tax liabilities: Property and equipment (7 ) (3 ) Total deferred tax liabilities (7 ) (3 ) Net deferred tax assets $ — $ —
Schedule of rollforward of the total gross unrecognized tax benefits	Year Ended December 31, 2021 2020 Beginning Balance 289 $ 164 Gross Increases - Tax Position in Current Period 198 125 Ending Balance $ 487 $ 289

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share attributable to common stockholders	Year Ended December 31, 2021 2020 Numerator: Net loss $ (21,773 ) $ (13,031 ) Accretion and dividends on redeemable convertible preferred stock (2,489 ) (8,914 ) Net loss attributable to common stockholders $ (24,262 ) $ (21,945 ) Denominator: Weighted-average common shares outstanding 26,298,032 3,201,430 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (6.85 )
Schedule of diluted net loss per share attributable to common stockholders	December 31, 2021 2020 Shares of redeemable convertible preferred stock — 11,299,425 Non-vested shares under restricted stock grants 84,167 1,094,167 Shares related to convertible promissory notes — 4,656,918 Shares subject to options to purchase common stock 5,541,937 3,137,811 Shares subject to warrants to purchase common stock 1,938,143 871,167 Total 7,564,247 21,059,488

Business Organization, Nature_2

Business Organization, Nature of Operations (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		10 Months Ended
	Mar. 25, 2021	May 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2018
Business Organization, Nature of Operations (Details) [Line Items]
Convertible promissory notes for net proceeds			$ 11.1
Paycheck protection program loans		$ 0.4
Public price per share (in Dollars per share)					$ 0.0125
Net proceeds	$ 44.3
Underwriting discounts	3.3
Offering expenses	$ 1.3
Ownership percentage	10.00%
Initial Public Offering [Member] | Common Stock [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Shares issued (in Shares)				9,775,000
Public price per share (in Dollars per share)				$ 5

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)
Accounting Policies [Abstract]
Number of segments	1
Interest and other income	$ 0.2
Offering costs	$ 0	$ 0.5
Redeemable convertible preferred stock share (in Shares) | shares	11,436,956

Fair value measurements (Detail

Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	$ 16,830
Total short-term investments	15,921
Cash equivalents – money market funds		$ 5,181
Warrant liability		1,549
Derivative liability		121
Money market funds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	16,830
Certificates of deposit [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	250
Commercial Paper [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	2,210
Corporate notes [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	12,024
Municipal Bonds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	1,437
Level 1 [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	16,830
Total short-term investments
Cash equivalents – money market funds		5,181
Warrant liability
Derivative liability
Level 1 [Member] | Money market funds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	16,830
Level 1 [Member] | Certificates of deposit [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] | Commercial Paper [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] | Corporate notes [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] | Municipal Bonds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 2 [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Total short-term investments	15,921
Cash equivalents – money market funds
Warrant liability
Derivative liability
Level 2 [Member] | Money market funds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Level 2 [Member] | Certificates of deposit [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	250
Level 2 [Member] | Commercial Paper [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	2,210
Level 2 [Member] | Corporate notes [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	12,024
Level 2 [Member] | Municipal Bonds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments	1,437
Level 3 [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Total short-term investments
Cash equivalents – money market funds
Warrant liability		1,549
Derivative liability		$ 121
Level 3 [Member] | Money market funds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Level 3 [Member] | Certificates of deposit [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] | Commercial Paper [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] | Corporate notes [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] | Municipal Bonds [Member]
Fair value measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of cash, cash equivalents and short-term investments - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents:
Total cash and cash equivalents	$ 17,675	$ 5,710
Short-term investments:
Total short-term investments	15,921
Cash [Member]
Cash and cash equivalents:
Total cash and cash equivalents	845	529
Money Market Funds [Member]
Cash and cash equivalents:
Total cash and cash equivalents	16,830	5,181
Certificates of Deposit [Member]
Short-term investments:
Total short-term investments	250
Commercial Paper [Member]
Short-term investments:
Total short-term investments	2,210
Corporate Notes [Member]
Short-term investments:
Total short-term investments	12,024
Municipal Bonds [Member]
Short-term investments:
Total short-term investments	$ 1,437

Cash, Cash Equivalents and Sh_4

Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of contractual maturities of short-term investments $ in Thousands	Dec. 31, 2021USD ($)
Schedule of contractual maturities of short-term investments [Abstract]
Due within one year	$ 15,921
Due after one year through five years
Total	$ 15,921

Cash, Cash Equivalents and Sh_5

Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of unrealized gains and losses related to short-term investments	Dec. 31, 2021USD ($)
Amortized Cost [Member]
Short-term investments:
Total short-term investments	$ 15,932,000
Amortized Cost [Member] | Certificates of Deposit [Member]
Short-term investments:
Total short-term investments	250,000
Amortized Cost [Member] | Commercial Paper [Member]
Short-term investments:
Total short-term investments	2,210,000
Amortized Cost [Member] | Corporate Notes [Member]
Short-term investments:
Total short-term investments	12,035,000
Amortized Cost [Member] | Municipal Bonds [Member]
Short-term investments:
Total short-term investments	1,437
Gross Unrealized Gains [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Gains [Member] | Certificates of Deposit [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Gains [Member] | Commercial Paper [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Gains [Member] | Corporate Notes [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Gains [Member] | Municipal Bonds [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Losses [Member]
Short-term investments:
Total short-term investments	(11,000)
Gross Unrealized Losses [Member] | Certificates of Deposit [Member]
Short-term investments:
Total short-term investments
Gross Unrealized Losses [Member] | Corporate Notes [Member]
Short-term investments:
Total short-term investments	(11,000)
Aggregate Estimated Fair Value [Member]
Short-term investments:
Total short-term investments	15,921,000
Aggregate Estimated Fair Value [Member] | Certificates of Deposit [Member]
Short-term investments:
Total short-term investments	250,000
Aggregate Estimated Fair Value [Member] | Commercial Paper [Member]
Short-term investments:
Total short-term investments	2,210,000
Aggregate Estimated Fair Value [Member] | Corporate Notes [Member]
Short-term investments:
Total short-term investments	12,024,000
Aggregate Estimated Fair Value [Member] | Municipal Bonds [Member]
Short-term investments:
Total short-term investments	$ 1,437,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 74,000	$ 13,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 630	$ 65
Less: accumulated depreciation	(101)	(27)
Total property and equipment, net	529	38
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	237	43
Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	115
Test equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 278	$ 22

Other Current Liabilities (Deta

Other Current Liabilities (Details) - Schedule of other current liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other current liabilities [Abstract]
Accrued research and development	$ 289	$ 197
Accrued compensation	2,211	184
Accrued vacation	276	192
Other	131	93
Total other current liabilities	$ 2,907	$ 666

Paycheck Protection Program L_2

Paycheck Protection Program Loan (Details) - USD ($)	1 Months Ended
	May 27, 2020	Apr. 23, 2020
Paycheck Protection Program Loan [Abstract]
Unsecured loan	$ 351,000	$ 351,000
Interest rate		1.00%
Term	11 months	2 years
Deferral of payments		10 months

Convertible Promissory Notes (D

Convertible Promissory Notes (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	11 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Convertible Promissory Notes (Details) [Line Items]
Total proceeds		$ 11,800
Convertible notes accrue interest		4.00%
Convertible notes		$ 247,000	$ 747,000	$ 247,000
Amount of future services				500,000
Debt value		747,000		747,000
Additional non-employee services	$ 50,000
Beneficial conversion feature	$ 500,000
Conversion price (in Dollars per share)			$ 2.5736
Warrants to purchase common stock were cancelled (in Shares)	42,220
Issuance costs			$ 83,000
Commissions			$ 612,000
Convertible note conversion, description			(i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative.
Lowest price per share selling price percentage			80.00%
Interest expense			$ 800	700
Debt Instrument, Unamortized Discount			400
Change in fair value of derivative liability			100
Convertible Notes Payable [Member]
Convertible Promissory Notes (Details) [Line Items]
Other noncurrent liabilities		$ 150,000		$ 150,000
Convertible notes for non-employee services	$ 500,000
Prepaid assets and other current expenses	$ 300,000
Beneficial conversion feature			500
Shares issued (in Shares)				10,000
Warrants (in Shares)				204,500
Conversion price (in Dollars per share)		$ 2.97		$ 2.97
Common stock equivalents			60,000,000
Outstanding principal			12,500
Interest due			400
Common stock equivalents			$ 12,900
Converted shares (in Shares)			5,015,494

Convertible Promissory Notes _2

Convertible Promissory Notes (Details) - Schedule of convertible note	9 Months Ended
	Sep. 30, 2021
Next Qualified Equity Financing [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price.
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing.
Change of Control [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control.
Maturity Date [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date.
Automatic Conversion – IPO [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price.
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO.
Option Conversion [Member]
Convertible Promissory Notes (Details) - Schedule of convertible note [Line Items]
Description	If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect.
Conversion Price	An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.

Convertible Promissory Notes _3

Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability	12 Months Ended
	Dec. 31, 2020$ / shares
Financing Date [Member]
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Probability of Conversion at Financing	80.00%
Expected Term	March 2021
Conversion Ratio	$ 1.25
Discount Rate	1.68% to 11.67%
Maturity Date [Member]
Convertible Promissory Notes (Details) - Schedule of fair value of the embedded redemption derivative liability [Line Items]
Probability of Conversion at Financing	20.00%
Expected Term	February 2022
Conversion Ratio
Discount Rate

Convertible Promissory Notes _4

Convertible Promissory Notes (Details) - Schedule of fair value of the derivative liability - Warrant Issuance [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Servicing Liabilities at Fair Value [Line Items]
Derivative liability, beginning balance	$ 121
Fair Value at issuance date		685
Change in fair value	(121)	(564)
Derivative liability, ending balance		$ 121

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Mar. 24, 2021	Mar. 28, 2019	Dec. 31, 2021
Redeemable Convertible Preferred Stock (Details) [Line Items]
Convertible preferred stock, description		On March 28, 2019, the Company’s Second Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) increased the number of shares of common stock the Company is authorized to issue to 22,069,652; (ii) increased the number of shares of preferred stock the Company was authorized to issue to 7,930,348, of which 2,692,253 shares were designated as Series A preferred stock and 5,238,095 shares were designated as Series B preferred stock; (iii) amended and set a fixed conversion price of Series A preferred stock to $1.40; and (iv) extended the IPO Commitment Date from April 1, 2020 to no later than March 31, 2021.
Convertible common stock (in Shares)			11,436,956
Preferred stock, description	(i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future.
Series B Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Transaction price net of issuance costs			$ 9.3
Accumulated accretion			11.5
Preferred stock carrying value			20.8
Series A Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Accumulated accretion			8.2
Preferred stock carrying value			$ 14.5

Common Stock (Details)

Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 25, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018
Common Stock (Details) [Line Items]
Common stock, shares authorized		75,000,000	22,069,652
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001
Common stock, shares outstanding		32,772,060	6,393,069
Common stock, shares issued		32,772,060	6,393,069
common stock vote		one
Shares of common stock for non-employee		17,000
Value of common stock issued for non-employee services (in Dollars)		$ 85,000
Purchase price per share (in Dollars per share)				$ 0.0125
Subject to the repurchase option		75,833	985,834
Early exercise of common stock option		50,000	890,356
Repurchase liability (in Dollars)		$ 281,000	$ 417,000
Shares remain unvested		567,397	856,814
Weighted average vesting period		1 year 11 months 26 days
Restricted Stock [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee				3,640,000
Purchase price per share (in Dollars per share)		$ 0.0125
Founder [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee				400,000
Purchase price per share (in Dollars per share)		$ 0.0125
Subject to the Repurchase Option		8,333	108,333
IPO [Member]
Common Stock (Details) [Line Items]
Common stock, shares authorized		75,000,000
Common stock, par value (in Dollars per share)		$ 0.0001
Aggregate amount (in Dollars)	$ 12,900
Converted into shares	5,015,494
Series A and Series B Redeemable Convertible Preferred Stock [Member]
Common Stock (Details) [Line Items]
Converted into shares of common stock	11,436,956

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of common stock reserved for future issuance	Dec. 31, 2021shares
Schedule of common stock reserved for future issuance [Abstract]
Warrants to purchase common stock	1,938,143
Stock options outstanding	5,592,137
Stock options available for future grants under the 2019 Plan	115,822
Total	7,646,102

Common Stock Warrants (Details)

Common Stock Warrants (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 28, 2021	Apr. 16, 2019	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 28, 2019	Mar. 28, 2019	Mar. 14, 2018
Common Stock Warrants (Details) [Line Items]
Description of warrants issued				In connection with the closing of Series A preferred stock offering, the Company issued warrants (“Preferred A Placement Warrants”) to purchase a total of 133,648 shares of its common stock to NSC on March 14, 2018 and April 23, 2018.
Warrants to purchase shares								133,648
Common stock shares issued percentage				10.00%
Conversion price (in Dollars per share)				$ 2.5736
Warrants for common stock issued	52,500
Weighted average exercise price (in Dollars per share)	$ 0.0125
Fair value of warrants liabilities (in Dollars)				$ 3,100,000
Common Stock [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued					140,000
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Term of warrants				5 years
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Warrants to purchase shares						242,847
Exercise price per share (in Dollars per share)						$ 1.4
Increasing number of warrants						109,200
Additional shares of common stock				50,195
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Term of warrants		5 years
Shares issued		414,270
Preferred B Placement Warrants [Member] | Common Stock [Member]
Common Stock Warrants (Details) [Line Items]
Common stock shares issued percentage		10.00%
Common stock shares conversion		4,142,270
Preferred B Lead Investor Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued				49,528
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued				10,000
Initial exercise price (in Dollars per share)				$ 2.97
Common stock cancelled (in Dollars)			$ 42,220
Convertible Notes Placement Warrants [Member] | Common Stock [Member]
Common Stock Warrants (Details) [Line Items]
Shares issued				204,050
Convertible Notes Placement Warrants [Member] | Warrants Liabilities [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price per share (in Dollars per share)				$ 2.57
Underwriter warrants [Member]
Common Stock Warrants (Details) [Line Items]
Warrants to purchase shares				0.0979
Term of warrants				5 years
Exercise price per share (in Dollars per share)				$ 6
Sale of Stock, Price Per Share (in Dollars per share)				$ 956,973
Series A Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Common stock shares issued upon conversion shares				1,336,485
Conversion price (in Dollars per share)							$ 1.4
Series B Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price per share (in Dollars per share)		$ 2.1

Common Stock Warrants (Detail_2

Common Stock Warrants (Details) - Schedule of company's warrant activity - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Warrant Issuance, Outstanding begining	1,938,143	871,167
Warrant Issuance, Granted	1,009,473
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(42,220)
Warrant Issuance, Variable Settlement Provision Adjustment	99,723
Warrant Issuance, Outstanding ending	1,938,143	871,167
Preferred A Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance		March and April 2018 and August 2019
Warrant Issuance, Excercise Price (in Dollars per share)		$ 1.4
Warrant Issuance, Outstanding begining	293,042	242,847
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	50,195
Warrant Issuance, Outstanding ending	293,042	242,847
Warrant Issuance, Expiration	March and April 2023
Preferred A Lead Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance		February 2021
Warrant Issuance, Excercise Price (in Dollars per share)		$ 0.0125
Warrant Issuance, Outstanding begining	52,500
Warrant Issuance, Granted	52,500
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	52,500
Warrant Issuance, Expiration	March 2023
Preferred B Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance		April 2019
Warrant Issuance, Excercise Price (in Dollars per share)		$ 2.1
Warrant Issuance, Outstanding begining	463,798	414,270
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	49,528
Warrant Issuance, Outstanding ending	463,798	414,270
Warrant Issuance, Expiration	April 2024
Convertible Notes Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance		August 2020
Warrant Issuance, Excercise Price (in Dollars per share)		$ 2.57
Warrant Issuance, Outstanding begining	171,830	214,050
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired	(42,220)
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	171,830	214,050
Warrant Issuance, Expiration	August 2025
Underwriter warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance		March 2021
Warrant Issuance, Excercise Price (in Dollars per share)		$ 6
Warrant Issuance, Outstanding begining	956,973
Warrant Issuance, Granted	956,973
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending	956,973
Warrant Issuance, Expiration	March 2026
Consulting Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance			February 2018
Warrant Issuance, Excercise Price (in Dollars per share)			$ 0.0125
Warrant Issuance, Outstanding begining			303,000
Warrant Issuance, Granted
Warrant Issuance, Exercised		(295,985)
Warrant Issuance, Canceled/ Expired		(7,015)
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending			303,000
Warrant Issuance, Expiration		February 2023
Preferred A Placement Warrants One [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance			March and April 2018 and August 2019
Warrant Issuance, Excercise Price (in Dollars per share)			$ 1.4
Warrant Issuance, Outstanding begining		242,847	242,847
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending		242,847	242,847
Warrant Issuance, Expiration		March and April 2023
Preferred B Placement Warrants One [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance			April 2019
Warrant Issuance, Excercise Price (in Dollars per share)			$ 2.1
Warrant Issuance, Outstanding begining		414,270	414,270
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending		414,270	414,270
Warrant Issuance, Expiration		April 2024
Convertible Notes Placement Warrants One [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance			August 2020
Warrant Issuance, Excercise Price (in Dollars per share)			$ 2.57
Warrant Issuance, Outstanding begining		214,050
Warrant Issuance, Granted		214,050
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment
Warrant Issuance, Outstanding ending		214,050
Warrant Issuance, Expiration		August 2025
Warrant Issuance [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Outstanding begining		871,167	960,117
Warrant Issuance, Granted		214,050
Warrant Issuance, Exercised		(295,985)
Warrant Issuance, Canceled/ Expired		(7,015)
Warrant Issuance, Outstanding ending		871,167	960,117

Common Stock Warrants (Detail_3

Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	$ 1,549	$ 32
Warrant Issuance, Fair value of warrants granted		6
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	1,581	1,511
Warrant Issuance, Reclassified to additional paid-in capital	(3,130)
Warrant Issuance, Warrant liability ending		1,549
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	518	12
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	575	506
Warrant Issuance, Reclassified to additional paid-in capital	(1,093)
Warrant Issuance, Warrant liability ending		518
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	708	20
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	800	688
Warrant Issuance, Reclassified to additional paid-in capital	(1,508)
Warrant Issuance, Warrant liability ending		708
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the warrant liability [Line Items]
Warrant Issuance, Warrant liability begining	323
Warrant Issuance, Fair value of warrants granted		6
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	206	317
Warrant Issuance, Reclassified to additional paid-in capital	(529)
Warrant Issuance, Warrant liability ending		$ 323

Common Stock Warrants (Detail_4

Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Dividend Yield
Expected Volatility	59.21%	67.75%
Risk-Free Interest Rate	0.14%	0.13%
Preferred A Placement Warrants	2 years	2 years 2 months 12 days
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Dividend Yield
Expected Volatility	58.51%	55.76%
Risk-Free Interest Rate	0.30%	0.17%
Preferred A Placement Warrants	3 years	3 years 3 months 18 days
Convertible Note Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of Black-Scholes option pricing model assumptions [Line Items]
Dividend Yield
Expected Volatility	52.28%	52.93%
Risk-Free Interest Rate	0.82%	0.36%
Preferred A Placement Warrants	4 years 4 months 24 days	4 years 8 months 12 days

Common Stock Warrants (Detail_5

Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants - Black-Scholes Fair Value Assumptions [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants [Line Items]
Issuance Date	March 2021
Fair Value (in Dollars)	$ 2,349
Dividend Yield
Expected Volatility	52.58%
Risk-Free Interest Rate	0.82%
Expected Life	5 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 18, 2019	Dec. 31, 2021	Dec. 31, 2020	Mar. 25, 2021	Dec. 07, 2020	Sep. 30, 2020
Stock-Based Compensation (Details) [Line Items]
Common stock, shares issued		32,772,060	6,393,069
Shares granted		115,822
Number of options		7,646,102
Unamortized compensation expense (in Dollars)		$ 1,854,000	$ 713,000
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value (in Dollars per share)		$ 2.54
Grant date fair value of options granted (in Dollars per share)			$ 1.78
Number of options		134,531	1,417,500
Proceeds from stock options exercised (in Dollars)		$ 100,000	$ 700,000
Fair value (in Dollars)		$ 839,380	$ 1,079,120
Fair value of options vested (in Dollars per share)		$ 700,000	$ 400,000
Unamortized compensation expense (in Dollars)		$ 7,800,000
Weighted average period		2 years 11 months 15 days
Common Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Number of options		2,000,000
2019 Equity Incentive Plan [member]
Stock-Based Compensation (Details) [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	4,000,000
Fair value percentage	110.00%
Exercise price percentage	10.00%
Contractual term	10 years
Shares granted		115,822
2019 Equity Incentive Plan [member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value percentage	100.00%
Common stock, shares issued					4,500,000	4,000,000
2019 Equity Incentive Plan [member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares issued					6,000,000	4,500,000
IPO [Member] | Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued				6,000,000
IPO [Member] | Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued				7,400,000
IPO [Member] | Common Stock [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued		9,775,000

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock option activity [Abstract]
Number of Options, Outstanding Beginning	3,188,011	3,027,200
Weighted Average Exercise Price, Outstanding Beginning	$ 0.66	$ 0.41
Weighted Average Remaining Life, Outstanding Beginning		9 years 7 months 6 days
Intrinsic Value, Outstanding Beginning	$ 8,155
Number of Options, Outstanding Ending	5,592,137	3,188,011
Weighted Average Exercise Price, Outstanding Ending	$ 2.29	$ 0.66
Weighted Average Remaining Life, Outstanding Ending	8 years 7 months 6 days	9 years
Intrinsic Value, Outstanding Ending	$ 9,912	$ 8,155
Number of Options, Exercisable	2,046,994
Weighted Average Exercise Price, Exercisable	$ 0.58
Weighted Average Remaining Life, Exercisable	7 years 10 months 24 days
Intrinsic Value, Exercisable	$ 6,604
Number of Options, Vested and expected to vest	5,541,937
Weighted Average Exercise Price, Vested and expected to vest	$ 2.3
Weighted Average Remaining Life, Vested and expected to vest	8 years 8 months 12 days
Intrinsic Value, Vested and expected to vest	$ 9,741
Number of Options, Granted	2,684,500	1,732,478
Weighted Average Exercise Price, Granted	$ 4.05	$ 0.92
Number of Options, Exercised	(134,541)	(1,417,500)
Weighted Average Exercise Price, Exercised	$ 0.56	$ 0.48
Number of Options, Cancelled	(145,833)	(154,167)
Weighted Average Exercise Price, Cancelled	$ 0.59	$ 0.38

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of weighted average assumptions for fair value of options estimated - Options [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock-Based Compensation (Details) - Schedule of weighted average assumptions for fair value of options estimated [Line Items]
Dividend yield
Expected volatility	66.38%	68.23%
Risk-free interest rate	0.93%	0.50%
Expected life	6 years 18 days	5 years 10 months 20 days

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense to employees and non-employees - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,854	$ 713
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	716	86
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,138	$ 627

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	May 14, 2021	Dec. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Lease term	40 months
Base rent	$ 14,000
Security deposit	$ 47,000
Rent expense		$ 154,000	$ 99,000

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of future minimum lease payments $ in Thousands	Dec. 31, 2021USD ($)
Schedule of future minimum lease payments [Abstract]
2022	$ 173
2023	179
2024	138
Total	$ 490

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Valuation allowance increased	$ 4,134,000	$ 2,326,000
Federal net operating loss carryforwards	37,500,000	21,500,000
Research and development credit carryforwards	560,000	238,000
California credit carryforwards	$ 640,000	418,000
Stockholders stock percentage	50.00%
Uncertain tax position percentage	50.00%
Unrecognized tax benefit liabilities	$ 487,000	$ 289,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of the effective tax rate of the company’s provision (benefit) for income taxes differs from the federal rate	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of the effective tax rate of the company’s provision (benefit) for income taxes differs from the federal rate [Abstract]
At Statutory rate	21.00%	21.00%
Valuation allowance	(18.00%)	(17.00%)
Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes	(3.00%)	(3.00%)
Other	1.00%	(1.00%)
Effective tax rate

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of significant components of the company’s deferred tax assets and liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Gross deferred tax assets:
Net operating loss carryforwards	$ 7,765	$ 4,523
Research and development credit carryforward	712	367
Accrued bonus	403
Stock-based compensation	72	74
Other	76	27
Total gross deferred tax assets	9,029	4,991
Less valuation allowance	(9,022)	(4,988)
Total net deferred tax assets	7	3
Deferred tax liabilities:
Property and equipment	(7)	(3)
Total deferred tax liabilities	(7)	(3)
Net deferred tax assets

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of rollforward of the total gross unrecognized tax benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of rollforward of the total gross unrecognized tax benefits [Abstract]
Beginning Balance	$ 289	$ 164
Gross Increases - Tax Position in Current Period	198	125
Ending Balance	$ 487	$ 289

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Performance based option awards	50,200	50,200

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss	$ (21,773)	$ (13,031)
Accretion and dividends on redeemable convertible preferred stock	(2,489)	(8,914)
Net loss attributable to common stockholders	$ (24,262)	$ (21,945)
Denominator:
Weighted-average common shares outstanding (in Shares)	26,298,032	3,201,430
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.92)	$ (6.85)

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of diluted net loss per share attributable to common stockholders [Abstract]
Shares of redeemable convertible preferred stock		11,299,425
Non-vested shares under restricted stock grants	84,167	1,094,167
Shares related to convertible promissory notes		4,656,918
Shares subject to options to purchase common stock	5,541,937	3,137,811
Shares subject to warrants to purchase common stock	1,938,143	871,167
Total	7,564,247	21,059,488

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	1 Months Ended
	Feb. 14, 2022$ / sharesshares
Subsequent Events (Details) [Line Items]
Stock option awards granted | shares	720,000
Stock option exercise price | $ / shares	$ 2.6